Concept
Sepsis
Sepsis is life-threatening organ dysfunction from a dysregulated host response to infection. Study layers here separate three questions: blood transcriptomic response states that track early mortality, genetic evidence that IL-6 receptor signalling may causally influence sepsis risk/severity, and early metabolite markers of sepsis-associated kidney injury.
Students meet “sepsis” as one syndrome and one pathway. Host-response subgroups, IL-6 receptor genetics, and SA-AKI metabolomics answer different clinical questions. Mixing them invents false agreement about diagnosis and treatment.
Evidence
What the evidence shows
Drawn from 3 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Blood leukocyte transcriptomes split ICU pneumonia sepsis into SRS1 vs SRS2 with different early mortality.
In prospective UK ICU adults with community-acquired pneumonia sepsis, unsupervised transcriptomics defined SRS1 (~41%) as an immunosuppressed state with higher 14-day mortality than SRS2 (discovery HR 2.4; validation HR 2.8), classifiable with a seven-gene set.
- Genetic IL-6 receptor blockade links to lower sepsis risk— different question — population genetic proxies for IL6R blockade, not ICU transcriptomic subtypes
- Three blood metabolites flag sepsis-associated kidney injury early— different organ focus — early SA-AKI metabolites, not whole-blood SRS classes
Study Role Design N Population Outcome Two blood gene signatures track sepsis outcomes Supports CohortGAinS prospective ICU transcriptomic discovery + validation N=265 · Discovery cohort; validation n=106 further ICU patients UK ICU adults with community-acquired pneumonia sepsis and organ dysfunction Transcriptomic sepsis response signatures (SRS1/SRS2) and 14-day mortality Genetic IL-6 receptor blockade links to lower sepsis risk Qualifiesdifferent question — population genetic proxies for IL6R blockade, not ICU transcriptomic subtypes Mendelian randomisationIL6R genetic instruments as proxies for lifelong IL-6 receptor blockade; UK Biobank primary N=486484 · UK Biobank ≈486,484 adults including 11,643 sepsis cases; secondary FinnGen and COVID-19 HGI UK Biobank adults (with secondary European/COVID genetics cohorts) Odds of sepsis (and severe sepsis / severe COVID-19 phenotypes) Three blood metabolites flag sepsis-associated kidney injury early Qualifiesdifferent organ focus — early SA-AKI metabolites, not whole-blood SRS classes OtherMouse LPS SA-AKI multi-omics discovery plus targeted serum metabolomics validation in patients N=56 · Clinical validation: 28 SA-AKI vs 28 sepsis without SA-AKI; mouse discovery separate Patients with sepsis with or without SA-AKI (mouse model for discovery) Early SA-AKI identification by metabolite panel (IC3 AUC) Genetically proxied IL6R blockade associates with lower sepsis risk and severity.
Mendelian randomisation treating IL6R variants as lifelong proxies for receptor blockade found lower odds of sepsis in UK Biobank (OR 0.80) and stronger associations for critical-care sepsis phenotypes (e.g., OR 0.48), with a similar-sized protective association for severe COVID-19 where IL-6 blockade is already recommended.
- Two blood gene signatures track sepsis outcomes— related host-response theme, but SRS classes are acute transcriptomic states — not IL6R MR instruments
Study Role Design N Population Outcome Genetic IL-6 receptor blockade links to lower sepsis risk Supports Mendelian randomisationIL6R genetic instruments as proxies for lifelong IL-6 receptor blockade; UK Biobank primary N=486484 · UK Biobank ≈486,484 adults including 11,643 sepsis cases; secondary FinnGen and COVID-19 HGI UK Biobank adults (with secondary European/COVID genetics cohorts) Odds of sepsis (and severe sepsis / severe COVID-19 phenotypes) Two blood gene signatures track sepsis outcomes Qualifiesrelated host-response theme, but SRS classes are acute transcriptomic states — not IL6R MR instruments CohortGAinS prospective ICU transcriptomic discovery + validation N=265 · Discovery cohort; validation n=106 further ICU patients UK ICU adults with community-acquired pneumonia sepsis and organ dysfunction Transcriptomic sepsis response signatures (SRS1/SRS2) and 14-day mortality A three-metabolite serum panel can flag sepsis-associated AKI early in a small cohort.
After mouse kidney multi-omics discovery, a 56-patient serum cohort supported an IC3 model (inosine, creatine, 3-hydroxybutyric acid) for early SA-AKI identification (AUC 0.90).
- Two blood gene signatures track sepsis outcomes— different readout — kidney metabolites vs blood leukocyte SRS
Study Role Design N Population Outcome Three blood metabolites flag sepsis-associated kidney injury early Supports OtherMouse LPS SA-AKI multi-omics discovery plus targeted serum metabolomics validation in patients N=56 · Clinical validation: 28 SA-AKI vs 28 sepsis without SA-AKI; mouse discovery separate Patients with sepsis with or without SA-AKI (mouse model for discovery) Early SA-AKI identification by metabolite panel (IC3 AUC) Two blood gene signatures track sepsis outcomes Qualifiesdifferent readout — kidney metabolites vs blood leukocyte SRS CohortGAinS prospective ICU transcriptomic discovery + validation N=265 · Discovery cohort; validation n=106 further ICU patients UK ICU adults with community-acquired pneumonia sepsis and organ dysfunction Transcriptomic sepsis response signatures (SRS1/SRS2) and 14-day mortality
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
SRS classes describe acute ICU transcriptomic states after pneumonia sepsis; IL6R MR estimates lifelong pathway effects on sepsis risk across a volunteer biobank. Both can be true without being the same assay or the same treatment decision.
- Two blood gene signatures track sepsis outcomes
- Genetic IL-6 receptor blockade links to lower sepsis risk
Study Role Design N Population Outcome Two blood gene signatures track sepsis outcomes Supports CohortGAinS prospective ICU transcriptomic discovery + validation N=265 · Discovery cohort; validation n=106 further ICU patients UK ICU adults with community-acquired pneumonia sepsis and organ dysfunction Transcriptomic sepsis response signatures (SRS1/SRS2) and 14-day mortality Genetic IL-6 receptor blockade links to lower sepsis risk Supports Mendelian randomisationIL6R genetic instruments as proxies for lifelong IL-6 receptor blockade; UK Biobank primary N=486484 · UK Biobank ≈486,484 adults including 11,643 sepsis cases; secondary FinnGen and COVID-19 HGI UK Biobank adults (with secondary European/COVID genetics cohorts) Odds of sepsis (and severe sepsis / severe COVID-19 phenotypes) IC3 targets early recognition of SA-AKI; SRS targets host-response prognosis. Shared sepsis context does not make kidney metabolites interchangeable with blood immune subtypes.
- Three blood metabolites flag sepsis-associated kidney injury early
- Two blood gene signatures track sepsis outcomes
Study Role Design N Population Outcome Three blood metabolites flag sepsis-associated kidney injury early Supports OtherMouse LPS SA-AKI multi-omics discovery plus targeted serum metabolomics validation in patients N=56 · Clinical validation: 28 SA-AKI vs 28 sepsis without SA-AKI; mouse discovery separate Patients with sepsis with or without SA-AKI (mouse model for discovery) Early SA-AKI identification by metabolite panel (IC3 AUC) Two blood gene signatures track sepsis outcomes Supports CohortGAinS prospective ICU transcriptomic discovery + validation N=265 · Discovery cohort; validation n=106 further ICU patients UK ICU adults with community-acquired pneumonia sepsis and organ dysfunction Transcriptomic sepsis response signatures (SRS1/SRS2) and 14-day mortality
Common misconceptions
One blood test or gene signature diagnoses and treats all sepsis the same way.
SRS subtypes, IL6R genetics, and SA-AKI metabolites answer different questions (prognostic immune state, pathway causality, organ complication). None replaces clinical infection source control and supportive care by itself.
IL6R Mendelian randomisation proves tocilizumab should be given for every bacterial sepsis case today.
MR supports a causal hypothesis and trial priority using lifelong genetic proxies; it is not a completed bedside RCT protocol for all sepsis etiologies.
An AUC of 0.90 means IC3 can replace creatinine and urine-output AKI criteria everywhere.
Performance came from a modest 56-patient cohort after mouse discovery work; external prospective validation is still required before routine replacement of clinical AKI criteria.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Why can SRS mortality differences and IL6R MR sepsis odds both be valid without being one claim?
SRS compares acute ICU transcriptomic subgroups after pneumonia sepsis; IL6R MR estimates lifelong pathway effects on sepsis phenotypes in biobank genetics. Shared “host response” language does not make the designs or decision rules interchangeable.
A student says IC3’s AUC 0.90 means sepsis-associated AKI is solved. What limit should they cite?
The model comes from a small serum cohort after mouse multi-omics discovery and needs external validation; it is an early-recognition aid hypothesis, not a universal replacement for clinical AKI criteria or a therapy.
The studies
3 studies in this library bear on Sepsis, ordered by citations.
- Two blood gene signatures track sepsis outcomes
In UK ICU adults with pneumonia sepsis, leukocyte transcriptomes split into SRS1 (immunosuppressed, ~41%) and SRS2; SRS1 had roughly 2–3× higher 14-day mortality, and a 7-gene set classified the groups.
- Genetic IL-6 receptor blockade links to lower sepsis risk
Mendelian randomisation treating IL6R variants as a natural experiment for receptor blockade found lower odds of sepsis (OR 0.80) and critical-care sepsis (OR 0.48) in UK Biobank, with a similar-sized protective association for severe COVID-19.
- Three blood metabolites flag sepsis-associated kidney injury early
Mouse kidney multi-omics plus a 56-patient serum cohort produced an IC3 model (inosine, creatine, 3-hydroxybutyric acid) that early-identified sepsis-associated AKI with AUC 0.90.
Learn alongside
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published